- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 2, Pages 214
Publisher
MDPI AG
Online
2021-01-08
DOI
10.3390/cancers13020214
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
- (2020) John Timmerman et al. AMERICAN JOURNAL OF HEMATOLOGY
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy
- (2020) Stephen D. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
- (2020) Ajay K Gopal et al. CLINICAL CANCER RESEARCH
- Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
- (2020) Isaure Vanmeerbeek et al. OncoImmunology
- Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL).
- (2020) David J. Sermer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
- (2020) Wendy Osborne et al. JOURNAL OF CLINICAL ONCOLOGY
- Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.
- (2020) Krish Patel et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
- (2020) Andrew L. Coveler et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program
- (2020) Massimo Granai et al. Infectious Agents and Cancer
- TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma
- (2020) Zhi-Zhang Yang et al. CLINICAL CANCER RESEARCH
- Tim-3 finds its place in the cancer immunotherapy landscape
- (2020) Nandini Acharya et al. Journal for ImmunoTherapy of Cancer
- Inflammatory Cells in Diffuse Large B Cell Lymphoma
- (2020) Roberto Tamma et al. Journal of Clinical Medicine
- New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
- (2020) Iñaki Etxeberria et al. ESMO Open
- Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
- (2020) Stephen M. Ansell et al. Blood Advances
- Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
- (2019) Stephen M. Ansell et al. JOURNAL OF CLINICAL ONCOLOGY
- TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma
- (2019) Sarah E Josefsson et al. Cancer Immunology Research
- Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
- (2019) Anas Younes et al. Lancet Haematology
- Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
- (2019) Daisuke Ennishi et al. Cancer Discovery
- HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
- (2019) Siyu Deng et al. MOLECULAR CANCER THERAPEUTICS
- Modulation of immune checkpoint molecule expression in mantle cell lymphoma
- (2019) Bonnie K. Harrington et al. LEUKEMIA & LYMPHOMA
- First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
- (2019) Branimir I. Sikic et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
- (2019) Moo-Kon Song et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy
- (2019) Claire Lamaison et al. IMMUNOLOGY LETTERS
- PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T cell-inflamed phenotype
- (2019) James Godfrey et al. BLOOD
- Diffuse Large B cell Lymphoma: 2019 update on diagnosis, risk-stratification and treatment
- (2019) Yang Liu et al. AMERICAN JOURNAL OF HEMATOLOGY
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation
- (2019) Philippe Armand et al. BLOOD
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
- (2019) Zhong Zheng et al. Molecular Cancer
- Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
- (2019) Daisuke Sugiura et al. SCIENCE
- ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE-155 STUDY
- (2019) G. Gregory et al. HEMATOLOGICAL ONCOLOGY
- THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
- (2019) R. Advani et al. HEMATOLOGICAL ONCOLOGY
- THE NOVEL BISPECIFIC CD47-CD19 ANTIBODY TG-1801 POTENTIATES THE ACTIVITY OF UBLITUXIMAB-UMBRALISIB (U2) DRUG COMBINATION IN PRECLINICAL MODELS OF B-NHL
- (2019) E. Normant et al. HEMATOLOGICAL ONCOLOGY
- Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
- (2019) Amy L. Shergold et al. PHARMACOLOGICAL RESEARCH
- Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma
- (2019) Christelle Vincent-Fabert et al. Cell Communication and Signaling
- A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
- (2019) Joseph M Tuscano et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for the treatment of diffuse large B-cell lymphoma
- (2019) Semira Sheikh et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
- (2019) Pavel Klener INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
- (2019) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice
- (2019) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic strategies for the costimulatory molecule OX40 in T-cell mediated immunity
- (2019) Yu Fu et al. Acta Pharmaceutica Sinica B
- Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
- (2019) Alex F. Herrera et al. AMERICAN JOURNAL OF HEMATOLOGY
- Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- (2019) Ulrich Jaeger et al. BLOOD
- TJC4, a Differentiated Anti-CD47 Antibody with Novel Epitope and RBC Sparing Properties
- (2019) Zhen Meng et al. BLOOD
- A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
- (2019) Tae Min Kim et al. BLOOD
- CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- (2019) Martin Hutchings et al. BLOOD
- The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)
- (2019) Jose C Villasboas et al. BLOOD
- Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study
- (2019) Allison Barraclough et al. BLOOD
- Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
- (2019) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Contemporary management of nodal and primary splenic marginal zone lymphoma
- (2019) Lori A. Leslie et al. Expert Review of Hematology
- Follicular lymphoma: 2020 update on diagnosis and management
- (2019) Arnold Freedman et al. AMERICAN JOURNAL OF HEMATOLOGY
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Marginal Zone Lymphoma: State-of-the-Art Treatment
- (2019) Ariel Sindel et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade
- (2019) John Apostolidis et al. HEMATOLOGICAL ONCOLOGY
- Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
- (2019) Tomohiro Aoki et al. Cancer Discovery
- Follicular lymphoma
- (2019) Antonino Carbone et al. Nature Reviews Disease Primers
- Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies
- (2018) Anja Mottok et al. BLOOD
- Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
- (2018) Valeria Spina et al. BLOOD
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
- (2018) Andreia C. Lino et al. IMMUNITY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia
- (2018) Vanessa Buatois et al. MOLECULAR CANCER THERAPEUTICS
- Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
- (2018) Marco Bezzi et al. NATURE MEDICINE
- The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas
- (2018) Lan V. Pham et al. Frontiers in Oncology
- TIGIT: a novel immunotherapy target moving from bench to bedside
- (2018) Benjamin L. Solomon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Abstract 2774: The triple combination of the FAP-IL2v immunocytokine with PD-L1 checkpoint inhibitory and CD40 agonistic antibodies results in long-term tumor control in the orthotopic PancO2 model
- (2018) Valeria Nicolini et al. CANCER RESEARCH
- Abstract 2782: Examining the dynamic regulation of OX40 following receptor agonism and T-cell activation: Implications for antibody-mediated enhancement of T-cell function
- (2018) Marie-Claude Gaudreau et al. CANCER RESEARCH
- Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies
- (2018) David Savitsky et al. CANCER RESEARCH
- Abstract 3033: Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767
- (2018) Marcus P. Kelly et al. CANCER RESEARCH
- Abstract 3816: Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models
- (2018) Lawrence J. Thomas et al. CANCER RESEARCH
- A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
- (2018) Tycel Phillips et al. INVESTIGATIONAL NEW DRUGS
- ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile
- (2018) Steven E. Kauder et al. PLoS One
- Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
- (2018) Jun Zhang et al. Frontiers in Oncology
- Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy
- (2018) Laura A. Vitale et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
- (2018) Daisuke Ennishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Co-engaging CD47 and CD19 with a bispecific antibody abrogates B-cell receptor/CD19 association leading to impaired B-cell proliferation
- (2018) Eric Hatterer et al. mAbs
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial
- (2018) Sean H. Lim et al. Trials
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
- (2018) S. Michael Chin et al. Nature Communications
- Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab
- (2018) Yan Li et al. Cell Reports
- MEDI 4736 (durvalumab) in non-small cell lung cancer
- (2017) Arnaud Jeanson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The 2016 updated WHO classification of lymphoid neoplasias
- (2017) Leticia Quintanilla-Martinez HEMATOLOGICAL ONCOLOGY
- The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer
- (2017) Hanke L. Matlung et al. IMMUNOLOGICAL REVIEWS
- PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
- (2017) Tomas Jelinek et al. IMMUNOLOGY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cell–Derived CD70 Delivers an Immune Checkpoint Function in Inflammatory T Cell Responses
- (2017) Rachel E. O’Neill et al. JOURNAL OF IMMUNOLOGY
- Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment
- (2017) Antonin Papin et al. LEUKEMIA & LYMPHOMA
- The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma
- (2017) Xia Fang et al. MEDICINE
- Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
- (2017) Elie Dheilly et al. MOLECULAR THERAPY
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies
- (2017) Mengnan He et al. Oncotarget
- Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
- (2017) Zhi-Zhang Yang et al. Oncotarget
- Abstract B37: NI-1701, a bispecific antibody for selective neutralization of CD47 in B cell malignancies
- (2017) Krzysztof Masternak et al. Cancer Immunology Research
- TTI-621 (SIRPαFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets
- (2017) Gloria H. Y. Lin et al. PLoS One
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
- (2016) D. Chiron et al. BLOOD
- Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas
- (2016) L. C. Chong et al. BLOOD
- Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
- (2016) K. Georgiou et al. BLOOD
- CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
- (2016) Anna Kwiecinska et al. BRITISH JOURNAL OF HAEMATOLOGY
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Therapeutic targeting of CD70 and CD27
- (2016) Harald Wajant EXPERT OPINION ON THERAPEUTIC TARGETS
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
- (2016) Thomas Menter et al. HUMAN PATHOLOGY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
- (2016) Alexander M. Lesokhin et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Ipilimumab for Patients with Relapse after Allogeneic Transplantation
- (2016) Matthew S. Davids et al. NEW ENGLAND JOURNAL OF MEDICINE
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
- (2016) Wei Xing et al. Oncotarget
- The emerging role of immune checkpoint inhibition in malignant lymphoma
- (2016) Ida Hude et al. HAEMATOLOGICA
- Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma
- (2015) Li Zhang et al. BIOMEDICINE & PHARMACOTHERAPY
- DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma
- (2015) R. Amin et al. BLOOD
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
- (2015) J. Kiyasu et al. BLOOD
- Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy
- (2015) Locke J. Bryan et al. BLOOD REVIEWS
- Abstract 253: Synergistic antitumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site
- (2015) Lawrence J. Thomas et al. CANCER RESEARCH
- Abstract 946: SGN-CD70A, a pyrrolobenzodiazepine (PBD) dimer linked ADC, mediates DNA damage pathway activation and G2 cell cycle arrest leading to cell death
- (2015) Sharsti L. Sandall et al. CANCER RESEARCH
- Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2R null Immunodeficient Mice
- (2015) M. F. Sanmamed et al. CANCER RESEARCH
- Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
- (2015) Dohee Kwon et al. HISTOPATHOLOGY
- Intratumoral Injection of Ad-ISF35 (Chimeric CD154) Breaks Tolerance and Induces Lymphoma Tumor Regression
- (2015) Mauricio Urquiza et al. HUMAN GENE THERAPY
- Recurrent genomic rearrangements in primary testicular lymphoma
- (2015) David DW Twa et al. JOURNAL OF PATHOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Structural genomic alterations in primary mediastinal large B-cell lymphoma
- (2015) David D. W. Twa et al. LEUKEMIA & LYMPHOMA
- Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
- (2015) Luis Fayad et al. LEUKEMIA & LYMPHOMA
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
- (2015) Nicolas Fischer et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
- (2015) R. Stewart et al. Cancer Immunology Research
- Induction of potent systemic anti-melanoma immunity through intratumoral CD40 activation and checkpoint blockade
- (2015) Manisha Singh et al. Journal for ImmunoTherapy of Cancer
- An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
- (2015) Vincent Ribrag et al. Journal for ImmunoTherapy of Cancer
- Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
- (2015) Venky Ramakrishna et al. Journal for ImmunoTherapy of Cancer
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
- (2015) Stefanie N. Linch et al. Frontiers in Oncology
- Abstract 2647: SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL)
- (2015) Sharsti Sandall et al. CANCER RESEARCH
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
- (2015) Jie Liu et al. PLoS One
- Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma
- (2014) Mohamad B. Sonbol et al. AMERICAN JOURNAL OF HEMATOLOGY
- Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain
- (2014) Min Shi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
- (2014) Kieron Dunleavy et al. BLOOD
- Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma
- (2014) G. Franco et al. BLOOD
- T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
- (2014) L. Nygren et al. CLINICAL CANCER RESEARCH
- Programmed death-1 pathway in cancer and autoimmunity
- (2014) Ariel Pedoeem et al. CLINICAL IMMUNOLOGY
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
- (2014) Sven de Vos et al. Journal of Hematology & Oncology
- Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma
- (2014) Taiwu Xiao et al. TUMOR BIOLOGY
- Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
- (2014) Matthew J. Ahearne et al. VIRCHOWS ARCHIV
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies
- (2014) Sabina Sangaletti et al. OncoImmunology
- High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
- (2013) J. H. Myklebust et al. BLOOD
- Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma
- (2013) Michelle Fanale et al. BRITISH JOURNAL OF HAEMATOLOGY
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells
- (2013) L. Wang et al. HAEMATOLOGICA
- Treg and CTLA-4: Two intertwining pathways to immune tolerance
- (2013) Lucy S.K. Walker JOURNAL OF AUTOIMMUNITY
- Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells
- (2013) Nicola Gagliani et al. NATURE MEDICINE
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
- (2013) W. W. Pang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity
- (2013) Patricia Amé-Thomas et al. SEMINARS IN CANCER BIOLOGY
- Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type
- (2013) Catherine Thieblemont et al. SEMINARS IN CANCER BIOLOGY
- Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
- (2013) Li-Zhen He et al. Journal for ImmunoTherapy of Cancer
- Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness
- (2012) M. S. Czuczman et al. ANNALS OF ONCOLOGY
- Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression
- (2012) J Melo-Cardenas et al. CANCER GENE THERAPY
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia
- (2012) L. A. Vitale et al. CLINICAL CANCER RESEARCH
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
- (2012) D Kim et al. LEUKEMIA
- Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma
- (2012) Andres Forero-Torres et al. LEUKEMIA & LYMPHOMA
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
- (2011) Madhavi Challa-Malladi et al. CANCER CELL
- Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses
- (2011) Shannon E. Smith et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
- (2011) D. J. Andorsky et al. CLINICAL CANCER RESEARCH
- Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
- (2011) Xiang-Yang Wang et al. EXPERT OPINION ON PHARMACOTHERAPY
- Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells
- (2011) T S Lewis et al. LEUKEMIA
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
- (2010) Mark P. Chao et al. CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages
- (2010) B. E. Wahlin et al. CLINICAL CANCER RESEARCH
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Peripheral 4-1BB Signaling Negatively Regulates NK Cell Development through IFN-
- (2010) B. K. Choi et al. JOURNAL OF IMMUNOLOGY
- Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
- (2009) R. Houot et al. BLOOD
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels
- (2009) Ulrike Lorenz IMMUNOLOGICAL REVIEWS
- PD-1 signaling in primary T cells
- (2009) James L. Riley IMMUNOLOGICAL REVIEWS
- High Numbers of Tumor-Infiltrating Programmed Cell Death 1–Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
- (2009) Joaquim Carreras et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
- Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion
- (2009) S. D. Blackburn et al. JOURNAL OF VIROLOGY
- Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody
- (2008) Luis H Camacho EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Signaling through CD80: an approach for treating lymphomas
- (2008) Manzoor A Mir et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Autoimmunity and lymphomagenesis
- (2008) Lynn R. Goldin et al. INTERNATIONAL JOURNAL OF CANCER
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma
- (2008) John Kuruvilla et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started